Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UUOGO
ADC Name
TORL-2-307-ADC
Synonyms
TORL-2-307 ADC
   Click to Show/Hide
Organization
TORL Biotherapeutics LLC
Drug Status
Phase 1
Indication
In total 3 Indication(s)
Gastric cancer [ICD11:2B72]
Phase 1
Gastroesophageal junction cancer [ICD11:2B71]
Phase 1
Pancreatic cancer [ICD11:2C10]
Phase 1
Antibody Name
Undisclosed
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05156866
Phase 1
A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05156866  Clinical Status Phase 1
Clinical Description A phase 1, first in human, dose-escalation study of TORL-2-307-ADC in participants with advanced cancer.
References
Ref 1 A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.